- Completed enrollment for the phase 3 IGNITE4 clinical trial of IV eravacycline in patients with cIAI. IGNITE4 is designed to evaluate IV eravacycline compared to meropenem and is expected to enroll approximately 450 patients. The primary analysis will be conducted using a 12.5% non-inferiority margin. Tetraphase expects to report top-line results in the third quarter of 2017. Assuming a successful outcome, this study, along with data from IGNITE1, would support an NDA filing for IV eravacycline for cIAI.
- Initiated the phase 3 IGNITE3 clinical trial of IV eravacycline in patients with cUTI. IGNITE3 is designed to evaluate IV eravacycline compared to ertapenem and is expected to enroll approximately 1,000 patients. The primary analysis will be conducted using a 10% non-inferiority margin. Assuming a positive outcome, the IGNITE3 clinical data are expected to support a supplemental NDA (sNDA) submission for IV eravacycline in cUTI.
- Presented data at ECCMID 2017, including in vitro data for eravacycline demonstrating potent activity against drug-resistant bacteria, specifically Gram-negative bacteria Acinetobacter baumannii and Enterobacteriaceae, including carbapenem-resistant or extended beta-lactamase producing phenotypes, as well as Gram-positive bacteria Staphylococcus aureus and enterococci, including methicillin- or vancomycin-resistant phenotypes. Additionally, data presentations for TP-6076 highlighted its potency against multidrug-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae, with activity demonstrated in clinical isolates that were pan-resistant to multiple antibiotic classes.
- Awarded up to $4 million in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, for its pipeline candidate TP-6076.
- Initiated a multiple-ascending dose study evaluating a 7-day dose regimen of IV TP-6076 in healthy volunteers.
- Received Qualified Infectious Disease Product and Fast Track designation from the FDA and initiated a single-ascending dose study for the oral formulation of TP-271.
Revenues during the first quarter of 2017 were $1.5 million compared to $2.0 million for the same period in 2016. Revenues for each period consisted of contract and grant revenue under the Company's U.S. government awards for the development of Tetraphase compounds for the treatment of diseases caused by bacterial biothreat pathogens and for certain infections caused by life-threatening multidrug-resistant bacteria. This decrease was primarily due to the scope and timing of activities related to our BARDA subcontract conducted during the quarter ended March 31, 2017, offset in part by an increase in clinical development activities under our NIAID subcontract.Research and development (R&D) expenses for the first quarter of 2017 were $25.9 million compared to $13.5 million for the same period in 2016. The increase in R&D expenses was primarily due to increased costs related to our IGNITE3 and IGNITE4 phase 3 clinical studies for eravacycline. General and administrative (G&A) expenses for the first quarter of 2017 were $5.1 million compared to $5.3 million for the same period in 2016. For the first quarter of 2017, Tetraphase reported a net loss of $29.5 million, or $0.79 per share, compared to a net loss of $16.7 million, or $0.46 per share, for the same period in 2016. About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information. Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in previous clinical trials will be indicative of results obtained in future clinical trials; whether eravacycline or any other clinical candidate will advance through the clinical trial process on a timely basis or at all; whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if any clinical candidate obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-K, filed with the Securities and Exchange Commission on March 13, 2017. In addition, the forward-looking statements included in this press release represent our views as of May 4, 2017. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
|Tetraphase Pharmaceuticals, Inc.|
|Condensed Consolidated Statement of Operations (Unaudited)|
|(In thousands, except per share data)|
|Three Months Ended|
|Research and development||25,947||13,523|
|General and administrative||5,133||5,253|
|Total operating expenses||31,080||18,776|
|Loss from operations||(29,595||)||(16,814||)|
|Other income (expense)|
|Other income (expense), net||137||73|
|Net loss per share-basic and diluted||$||(0.79||)||$||(0.46||)|
|Weighted-average number of common shares used in net loss per share|
|applicable to common|
|stockholders-basic and diluted||37,093||36,598|
|Tetraphase Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheets (unaudited)|
|March 31,||December 31,|
|Cash and cash equivalents||$||128,159||$||142,086|
|Prepaid expenses and other current assets||3,829||6,582|
|Property and equipment, net||1,467||1,054|
|Other assets, noncurrent||199||199|
|Liabilities and Stockholders' equity|
|Accounts payable and accrued expenses||$||15,366||$||10,240|
|Total deferred revenue||851||1,255|
|Other liabilities, noncurrent||148||162|
|Total stockholders' equity||118,992||140,053|
|Total liabilities and stockholders' equity||$||135,357||$||151,710|
Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman617email@example.comArgot PartnersMaeve Conneighton206.firstname.lastname@example.orgMedia Contact:Sam Brown Inc.Mike Beyer312-961-2502Mikebeyer@sambrown.com